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IL-33 plays an important role in the initiation of type-2 immune responses, as well
as the enhancement of type 2 effector functions. Engagement of the IL-33 receptor on
macrophages facilitates polarization to an alternative activation state by amplifying IL-4
and IL-13 signaling to IL-4Rα. IL-4 and IL-13 also induce macrophage proliferation but
IL-33 involvement in this process has not been rigorously evaluated. As expected, in
vivo delivery of IL-33 induced IL-4Rα-dependent alternative macrophage activation in
the serous cavities. IL-33 delivery also induced macrophages to proliferate but, unex-
pectedly, this was independent of IL-4Rα signaling. In a filarial nematode infection model
in which IL-4Rα-dependent alternative activation and proliferation in the pleural cav-
ity is well described, IL-33R was essential for alternative activation but not macrophage
proliferation. Similarly, during Alternaria alternata induced airway inflammation, which
provokes strong IL-33 responses, we observed that both IL-4Rα and IL-33R were required
for alternative activation, while macrophage proliferation in the pleural cavity was still
evident in the absence of either receptor alone. Our data show that IL-33R and IL-4Rα
promote macrophage proliferation independently of each other, but both are essential for
induction of alternative activation.
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Introduction
Over the last 4 years a paradigm shift has occurred in macrophage
biology, with the realization that macrophages resident within
multiple tissues of the body can self-maintain without replen-
ishment from blood monocytes [1–4]. In many tissues, stromal
derived CSF1 and/or IL-34 are responsible for the maintenance
of resident macrophage numbers during the steady state [5]. We
found using experimental nematode infections that IL-4 can pro-
mote an increase in tissue macrophage numbers, above homeo-
static levels, via proliferation rather than recruitment from the
blood [2, 6]. The pro-fibrotic cytokine IL-13, which is another lig-
and for IL-4Rα, can also cause body cavity macrophages to divide
in vivo [6]. The interaction between IL-4Rα dependent cytokines
and CSF1 is thought to ensure the expansion of the macrophage
pool without the influx of inflammatory cells. Indeed, the com-
binatorial action of both CSF1 and IL-4 is required to control
macrophage numbers within the peritoneal cavity during nema-
tode infection [6].
IL-33 is a member of the IL-1 family of cytokines, and is known
to promote type-2 responses [7], in particular through the induc-
tion of IL-5 and IL-13 secretion from both T cells and innate lym-
phoid cells (ILCs). IL-33 has also been shown to indirectly and
directly activate eosinophils [8, 9], which are a source of IL-4 capa-
ble of driving the alternative activation of macrophages [10–12].
The ability of IL-33 to induce type 2 cytokines from multiple cell
types makes it unsurprising that IL-33 has documented roles in
the polarization of macrophages to an alternative activation phe-
notype [13, 14]. This is further enhanced by the ability of IL-33 to
upregulate IL-4Rα expression [13, 14]. Although macrophage pro-
liferation has also been described in the context of IL-33 responses,
it is presumed to be dependent upon IL-33 induction of type 2
cytokines either from ILCs [15] or basophils [16].
In this work we set out to define the contribution of IL-33
to alternative macrophage activation, and determine whether
the impact of IL-33 extended to macrophage proliferation.
We found that IL-33 delivery in vivo induced both the pro-
liferation and alternative activation of pleural and peritoneal
cavity macrophages. While IL-33-induced alternative activation
was IL-4Rα-dependent, IL-33-dependent macrophage prolifera-
tion occurred in the absence of either eosinophils or the IL-4Rα.
Thus, either IL-4 or IL-33 alone was sufficient to drive the prolif-
eration of macrophages in vivo. However, responsiveness to both
cytokines was required for macrophage alternative activation dur-
ing either allergic inflammation or nematode infection.
Results
IL-33 induces macrophage proliferation in vivo
To evaluate the capacity of IL-33 to induce macrophage prolif-
eration, we injected recombinant IL-33 (rIL-33) directly into the
peritoneal cavity (i.p.) of wild type (WT) BALB/c mice. Prolifera-
tion was assessed 48 h later, a time point at which macrophages
exhibit robust proliferation following a single delivery of IL-4. Pro-
liferation was assessed by Imagestream analysis of cellular DNA
content and visualized using TOPRO3. A significant increase in
F4/80+ cells that were in G2/M phase was observed in animals
treated with rIL-33 versus PBS (Fig. 1A and B). Proliferation was
also assessed via intracellular staining for the cell cycle protein
Ki67 within the F4/80hiMHC-IIlo resident macrophage population
(Fig. 1C and D). Ki67 staining can reflect cells that have recently
proliferated rather than cells that are actively dividing. We thus
additionally gated on macrophages which exhibited a high level of
Ki67 expression after staining with BD clone B56. Because it has
been demonstrated that these cells are in active cell cycle [6, 17],
Ki67high staining provided additional confirmation that treatment
induced cellular proliferation. Both Imagestream analysis and
Ki67 staining demonstrated that IL-33was sufficient to induce pro-
liferation of peritoneal macrophages (Fig. 1; see Supporting Infor-
mation Fig. 1 for macrophage gating strategy). rIL-33 delivery also
resulted in significantly increased expression of RELMα (Fig. 1E), a
molecule associated with alternative macrophage activation [18]
and known to be one of the most highly IL-4Rα dependent genes
in macrophages [19]. We also confirmed in vitro that, as shown
previously [13, 14], IL-33was able to enhance the expression of IL-
4Rα by F4/80+ peritoneal macrophages (Fig. 1F). Furthermore,
consistent with published data, two days following injection of
rIL-33 we detected an increase in the percentage expression and
number of GATA3+ and IL-5+ (Fig. 1G and H) ILC2s within the
peritoneal cavity. Delivery of rIL-33 also increased the numbers of
eosinophils within the peritoneal cavity from 2 × 105 to 5 × 105
(p < 0.01). These data demonstrated that rIL-33 delivery can ini-
tiate serous cavity macrophage division and alternative activation
and suggested that this may occur via induction of type 2 cytokine
secreting ILCs and eosinophils acting via enhanced IL-4Rα
signaling.
IL-33 promotion of macrophage proliferation does not
require eosinophils
The increase in eosinophils and IL-5 expressing ILCs in the peri-
toneal cavity following IL-33 treatment, along with the doc-
umented ability of eosinophils to produce IL-4 [10–12], led
us to address whether IL-33-dependent macrophage prolifera-
tion required eosinophils. We therefore injected rIL-33 i.p. into
eosinophil deficient mice (dblGATA) and assessed Ki67 expres-
sion within the peritoneal macrophage population. There was no
significant difference between BALB/c WT and dblGATA mice
in the percentage expression of Ki67 at two days following rIL-
33 delivery (Fig. 2A and B). However, there was a minor trend
toward a reduction in the percentage of RELMα+ macrophages
in the dblGATA mice (Fig. 2C and D) and a significant reduc-
tion in secreted RELMα protein (Fig. 2E). More dramatically,
there was a complete failure to induce Ym1 protein within
the peritoneal lavage fluid of eosinophil deficient mice treated
with IL-33 (Fig. 2F). These data indicated that IL-33-induced
proliferation of macrophages did not require eosinophils, but that
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Figure 1. IL-33 induces body cavity marcrophages to proliferate. ImageStream and flow cytometric analysis of the peritoneal macrophage popu-
lation harvested following intra-peritoneal delivery of rIL-33 or PBS as control. (A) Single cells were discriminated from cell aggregates based on
area and aspect ratio. Of those, in focus macrophages were selected based on high gradient RMS of the bright field image and F4/80 expression,
intracellular staining with TOPRO3 was used to visualize cellular DNA content, representative ImageStream images of macrophages. (B) Repre-
sentative histograms of cells in G2/M phase based on TOPRO3 and quantification of cells in G2/M phase shown as percentage of total F4/80+
and cell number. (A) Data are representative of two independent experiments with seven mice per experiment; (B) data are combined from two
independent experiments with seven mice per experiment, symbols represent individual mice, n = 6-8 per group. (C, D) Flow cytometric analysis
showing percent intracellular Ki67 and (E) RELMα within macrophages, isotype control staining (control) is showed for comparison. (C–E) Data are
combined from five independent experiments with eight or ten mice per experiment; symbols represent individual mice, n = 22 per group. (F)
Representative histogram (upper panel) and quantification (lower panel) of IL-4Rα surface expression on peritoneal cavity macrophages stimu-
lated in vitro with rIL-33 with indicated concentrations (F) Data are combined from three independent experiments, with three or five mice per
experiment, symbols represent culture wells prepared using cells from individual mice, n = 10 per group. One way ANOVA with Sidak’s multiple
comparison test comparing each condition to 0 ng/mL; error bars showmean ±SEM, n.s.: nonsignificant; ****p < 0.0001. (G, H) Intracellular staining
for GATA3 and IL-5 in CD90.2+ Lin− (CD11b Ly6G Ly6C Ter119 CD5 B220 CD49b TCRb CD3 NK1.1 CD11c F4/80) peritoneal cavity ILCs harvested
following intraperitoneal delivery of rIL-33. (G and H) Representative density plots (upper panels) and percentage and total number of GATA3 and
IL-5 positive cells (lower panels). (G, H) Data are representative of two independent experiments with ten mice per experiment with n = 5 per
group. Unless stated otherwise unpaired t-test was used, error bars show mean ±SEM *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. IL-33 mediated macrophage proliferation does not require eosinophils. Peritoneal cavity macrophages and lavage were harvested
following intra-peritoneal delivery of rIL-33 into wild type (BALB/c) and eosinophil deficient (dblGATA) mice. Flow cytometric analysis of (A)
intracellular Ki67 staining, (B) quantification of % Ki67 expression, (C) intracellular RELMα, and (D) quantification of % RELMα expression within
macrophage population. (E and F) ELISA of RELMα and Ym1 protein levels in peritoneal lavage. (A–D) Data are representative of two independent
experiments with 14 or 19 mice per experiment, symbols represent individual mice n = 3–5 per group. One way ANOVA with Sidak’s multiple
comparison test comparing IL-33 to PBS treatment for each strain and IL-33 treatment between strains, error bars show mean ±SEM, n.s.:
nonsignificant, *p < 0.05, **p < 0.01 (E, F) Data are combined from two independent experiments with 14 or 19 mice per experiment, n = 7–9 per
group. One way ANOVA with Sidak’s multiple comparison test comparing IL-33 treatment between strains, error bars showmean ±SEM, *p < 0.05.
eosinophils did contribute to alternative macrophage activation.
Because RELMα and Ym1 are secreted in response to IL-4Rα signal-
ing, their reduced protein levels in the dblGATA mice suggested
that eosinophils are an important source of IL-4 in mice treated
with IL-33. In contrast, there was no significant change in the
amount of macrophage proliferation in the absence of eosinophils,
leading us to question our original hypothesis that IL-33-mediated
proliferation occurs indirectly via downstream activation of the
macrophage IL-4Rα.
IL-33 does not require IL-4Ra to induce macrophage
proliferation
In order to address whether the ability of IL-33 to medi-
ate macrophage proliferation required IL-4 responsiveness, we
injected rIL-33 into the peritoneal cavity of Il4ra deficient and
WT BALB/c mice, and compared macrophage numbers 48 h
later. We found no significant difference between genotypes in
the expression of Ki67 within the resident macrophages follow-
ing rIL-33 treatment (Fig. 3A and B). In contrast, there was a
highly significant reduction in RELMα expressionwithin peritoneal
macrophages (Fig. 3C and D) and secreted RELMα and Ym1 pro-
tein (Fig. 3E) within the peritoneal lavage fluid of the IL-4Rα defi-
cient animals, confirming a requirement for IL-4Rα signaling for
induction of these alternative activation markers. Because IL-33
was still able to promote macrophage proliferation in the absence
of IL-4Rα, we addressed whether IL-33 could induce macrophage
proliferation directly in vitro. We cultured total peritoneal exudate
cells (PECs) with increasing concentrations of rIL-33 and assessed
the level of Ki67 within F4/80+ macrophages following 2 days of
culture (Fig. 3F). A small but significant increase in the percent-
age proliferation of peritoneal macrophages was seen when cells
were cultured with IL-33 but only at the highest dose of rIL-33
(200 ng/mL). These data suggested that when provided at a high
enough concentration IL-33 can either act directly onmacrophages
to induce their proliferation or is able to induce PECs to secrete a
downstream macrophage mitogen. We failed to detect an increase
in the levels of the known mitogens CSF1, CSF2, and IL-4 within
the culture well (data not shown). The ability of IL-33 to induce
proliferation in vitro, although sub-optimal, is in contrast to IL-4,
which consistently fails to do so (unpublished observation).
Because IL-4Rα signaling can induce IL-33R expression [13, 19]
we considered the possibility that IL-33R may act downstream of
IL-4-driven macrophage proliferation in vivo. To test this possibil-
ity, we injected long acting IL-4 complex (IL-4c) [20] i.p. into WT
BALB/c and IL-33R deficient animals and assessed proliferation
and alternative activation of peritoneal macrophages 48 h later.
IL-4c increasedmacrophage numbers, Ki67 expression and RELMα
expression equally in both strains (Supporting Information Fig. 2).
Thus, IL-4 acts independently of IL-33R signaling.
IL-33 induces pleural cavity macrophage proliferation
and alternative activation
We wished to assess whether our observations in the peritoneal
cavity applied more broadly to the other serous cavities. We
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Figure 3. IL-33 mediated macrophage proliferation does not require IL-4Rα. Peritoneal cavity macrophages and lavage were harvested following
intra-peritoneal delivery of rIL-33 into wild type (BALB/c) and IL-4Rα deficient (Il4ra−/−) mice. (A–D) Flow cytometric analysis of intracellular (A) Ki67
staining, (B) quantification of % Ki67 expression, (C) of intracellular RELMα, and (D) quantification of % RELMα expression and RELMα+ macrophage
(Mϕ) number. (E) ELISA analysis of RELMα andYm1protein levels in peritoneal lavage. (A–E) Data are combined from three independent experiments
with 16 or 20 mice per experiment, symbols represent individual mice, n = 10–14 per group. One-way ANOVA with Sidak’s multiple comparison
test comparing IL-33 to PBS for each strain and IL-33 treatment between strains, error bars show mean ±SEM, n.s.: nonsignificant, *p < 0.05, **p
< 0.01, *** p < 0.001, ****p < 0.0001 (F) Total wild-type peritoneal cells were cultured in vitro with rIL-33 with indicated concentrations or medium,
% Ki67 expression was determined in F4/80+ macrophages by flow cytometry. (F) Data are combined from four independent experiments with
three or five mice per experiment, symbols represent culture wells prepared using cells from individual mice, n = 11–15 biological replicates per
group. One way ANOVA with Sidak’s multiple comparison test comparing each dose of IL-33 to the media control, error bars show mean ±SEM,
*p < 0.05.
have previously found that allergen delivery induces a profound
immune response in the pleural space [21]. We thus delivered
rIL-33 by the intra-nasal (i.n.) route (Fig. 4A and B) and
assessed proliferation by Ki67 staining within the F4/80hiMHC-IIlo
macrophage population of the pleural space. IL-33 delivered
intra-nasally resulted in an increase in the percentage expres-
sion of Ki67 and RELMα within macrophages of the pleu-
ral cavity (Fig. 4A and B). These data confirmed that lung
derived IL-33 can influence immune cells within the cavity in
which the lungs are contained, and that IL-33 is able to induce
macrophage proliferation at tissue sites other than the peritoneal
cavity.
Alternaria induces macrophage proliferation
independently of the IL-4Rα
To assess the role of IL-33 in macrophage proliferation and alter-
native activation in more complex and relevant settings, we chose
two models in which IL-33 is known to be functional and involve
activation of serous cavity macrophages [22–24]. The first model
we chose was delivery of an extract of Alternaria alternata, a
fungal allergen, into the lung. IL-33 is a major component of
pleural immune response that follows pulmonary instillation
of Alternaria sp. [21]. Lung instillation of Alternaria extract
resulted in a significant increase in the frequency of macrophages
C© 2016 The Authors. European Journal of Immunology published by
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Figure 4. IL-33 delivered intra-nasally causes pleural cavity
macrophages to proliferate and alternatively activate. Flow cyto-
metric analysis of pleural macrophage population harvested following
intra-nasal delivery of rIL-33, showing percent intracellular (A) Ki67
and (B) RELMα. Representative density plots (left panels) are from a
single experiment representative of two independent experiments
with ten mice per experiment. (A, B) Quantitative data are combined
from these independent experiments; symbols represent individual
mice, n = 10 per group. Unpaired t-test, error bars show mean ±SEM *p
< 0.05, ***p < 0.001.
expressing the IL-4Rα within the pleural cavity of BALB/c animals
(Fig. 5A), consistent with the ability of IL-33 to induce IL-4Rα
expression (Fig. 1E and [13]). We therefore assessed the con-
tribution of the IL-4Rα during Alternaria induced airway inflam-
mation by comparing the pleural macrophage phenotype at 48 h
in WT and IL-4Rα-deficient mice. In both genotypes there was a
significant increase in the total number of macrophages within
the pleural cavity at 48 h following Alternaria delivery (Fig. 5B).
Furthermore, no significant difference in expression level of Ki67
between Alternaria exposed WT and IL-4Rα-deficient mice could
be detected (Fig. 5C). These data demonstrated that macrophages
present within the pleural cavity divide in response to intra-
nasal challenge with a fungal allergen and that this proliferative
response occurs independently of IL-4Rα signaling. We also deter-
mined the activation state of the pleural macrophages in these
experiments by assessing the intracellular production (Fig. 5D)
and global secretion of RELMα and Ym1 proteins into the pleu-
ral lavage (Fig. 5E). Alternaria instillation significantly increased
the levels of both intracellular macrophage RELMα and secreted
RELMα and Ym1 within WT mice, but this was significantly
reduced in IL-4Rα-deficient mice (Fig. 5D and E). Thus, alterna-
tive activation, but not proliferation, was reliant on IL-4Rα in this
allergen model. Because these findings mirrored the delivery of
IL-33 into the peritoneal cavity (Fig. 3A–D), we hypothesized that
the high levels of IL-33 induced following Alternaria instillation
were responsible for these observations.
IL-33R signaling is required for the Alternaria-induced
alternative activation of macrophages
To determine if the pleural cavity macrophage response to
Alternariawasmediated by IL-33, we delivered the fungal allergen
Figure 5. Alternaria can induce pleural cavity macrophages to prolif-
erate but not alternatively activate independently of IL-4Rα. BALBc and
Il4ra−/- mice had Alternaria extract delivered i.n. and pleural cavity cells
were harvested. (A) Pleural cavity macrophage IL-4Rα expression, (B)
Total pleural cavity macrophage number, (C) % Ki67 expression and
(D) % RELMα expression within the macrophage population were deter-
mined by flow cytometry. (E) RELMα and Ym1 protein levels within the
pleural lavage were determined by ELISA. (A) Data are representative of
two independent experiments, with 20 mice per experiment, symbols
represent individual mice, n = 5 per group. (B–E) Data are combined
from two to three independent experiments with 10 or 20 mice per
experiment, symbols represent individual mice n = 10–15 per group.
One way ANOVA with Sidak’s multiple comparison test comparing Alt
to PBS for each strain and Alt treatment between strains, error bars
showmean ±SEM, n.s.: nonsignificant, *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
intra-nasally to both WT and IL-33R-deficient mice and assessed
macrophage phenotype 48 h later. We found that, in the absence
of IL-33R, there was no induction of the alternative activation
marker RELMα by Alternaria. Both the frequency of expression
(Fig. 6A) and total number of RELMα+ macrophages (Fig. 6B)
were at baseline in the IL-33R-deficient cells, resulting in a signif-
icant reduction when compared to WT animals (Fig. 6A and B).
There was a trend for reduced RELMα protein within the pleu-
ral lavage fluid, and significantly reduced Ym1, in the absence of
IL-33R (Fig. 6C), suggesting that an impaired Th2 response had
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Figure 6. Alternaria induces IL-33R-dependent alternative activation and IL-33R-independent macrophage proliferation in the pleural cavity.
BALB/c and Il1rl1−/- mice had Alternaria extract delivered i.n. and pleural cavity cells were harvested. (A) % RELMα expression and (B) RELMα+
macrophage number were determined by flow cytometry. (C) RELMα and Ym1 protein levels within the pleural lavage were determined by ELISA.
(D–F) The total number of (D) pleural cavity SSChiSiglecF+ Eosinophils, (E) macrophage cell number (left panel) and %Ki67 expression (right panel),
and (F) Ki67+ macrophage number were determined by flow cytometry. (A–F) Data are combined from two independent experiments with 17 and
18 mice per experiment, symbols represent individual mice n = 5–10 per group. One way ANOVA with Sidak’s multiple comparison test comparing
Alt to PBS for each strain and Alt treatment between strains, error bars show mean ±SEM, n.s.: nonsignificant; *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
occurred in the absence of IL-33 signaling, which was further sup-
ported by failed recruitment of eosinophils to the pleural cavity
(Fig. 6D). Despite the clear defect in type 2 immune responses
in the IL-33R-deficient mice, there was only a small decline in
total macrophage numbers, and no significant difference in the
frequency of Ki67+ macrophages, between WT and IL-33R defi-
cient mice at this time point (Fig. 6E). There was, however, a
significant reduction in the total number of Ki67+ macrophages in
the IL-33R deficient mice (Fig. 6F). These data suggest a deficit in
the survival of macrophages in the absence of IL-33R, which may
be an indirect consequence of both reduced IL-4Rα expression and
reduced IL-4 availability. Thus in the allergy model, IL-33 receptor
signaling is essential for macrophage alternative activation but it’s
contribution to proliferation is not as direct as that seen with the
reductionist IL-33 delivery model.
IL-33R is required for the alternative activation of
pleural cavity macrophages during nematode
infection
Litomosoides sigmodontis is a nematode parasite that resides in
the pleural space and induces a local Th2 response. IL-4Rα-
dependent proliferation and alternative activation of pleural cav-
ity macrophages are prominent features at day 11 post infec-
tion [2, 6]. We thus chose this infection model to further address
the requirement for IL-33R in the proliferation or alternative acti-
vation of pleural cavity macrophages. We infected WT and IL-33R
deficient mice subcutaneously with L. sigmodontis and assessed
pleural cavity macrophages 11 days following infection (Fig. 7).
There was a significant increase in the number of pleural cav-
ity macrophages in WT animals, but there was no significant
reduction in the absence of IL-33R (Fig. 7A). Consistent with the
equivalent increase in macrophage cell number between strains,
we found comparable Ki67 expression between theWT and IL-33R
deficient animals 11 days following infection (Fig. 7B). However,
while there was a significant increase in the expression of RELMα
within the pleural cavity macrophages ofWT animals at day 11 fol-
lowing L. sigmodontis infection (Fig. 7C), no such increase in either
percentage (Fig. 7C) or number (Fig. 7D) of RELMα+ macrophages
was apparent in IL-33R deficient animals. Thus, we observed no
defect in pleural cavity macrophage proliferation but a failure to
induce alternative activation in the absence of IL-33R in two very
distinct model systems, a helminth infection and airway inflam-
mation.
Discussion
Studies of Cryptococcus neoformans infection [25], bleomycin-
induced lung fibrosis [26] and ovalbumin-induced airway inflam-
mation [13, 27] have demonstrated a role for IL-33 in the alter-
native activation of lung derived or alveolar macrophages. These
studies suggested that IL-33 modulates macrophage phenotype
by inducing a type 2 cytokine response in accessory cells such
as mast cells, basophils, or ILCs. Our studies using administra-
tion of recombinant cytokine, a fungal allergen and nematode
infection are consistent with these studies and demonstrate that
C© 2016 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
2318 Lucy H. Jackson-Jones et al. Eur. J. Immunol. 2016. 46: 2311–2321
Figure 7. Alternative macrophage
activation but not proliferation is
IL-33R dependent during nematode
infection of the pleural cavity. BALBc
and Il1rl1−/- mice were infected
subcutaneously with L. sigmodontis
infective larvae and pleural cavity
cells harvested 11 days post infection
(D11). Pleural cavity macrophages
were analyzed by flow cytometry. (A)
Total macrophage number (B) % Ki67
expression, (C) % RELMα expression
and (D) RELMα+ macrophage number.
(A–D) Data are combined from three
independent experiments with 17,
21, and 23 mice per experiment,
symbols represent individual mice, n
= 13-16 per group. One way ANOVA
with Sidak’s multiple comparison
test comparing D11 to Naı¨ve for each
strain and D11 infection between
strains, error bars show mean ±SEM,
n.s.: nonsignificant, *p < 0.05, **p <
0.01, ***p < 0.001, **** p < 0.0001.
IL-33-dependent alternative activation is also reliant on IL-4Rα
in the serous cavities. We further show that eosinophils are a
likely source of IL-33-induced IL-4 as they were required for the
complete induction of alternative activation within the peritoneal
cavity following delivery of exogenous IL-33. Other cell types are
also likely to be IL-33 targets, in particular ILC2s which produce
IL-5 and IL-13 in an IL-33-dependent manner following Alternaria
delivery [23]. Indeed, IL-5 produced by ILCs may further enhance
the number of IL-4 producing eosinophils. Our findings taken
together with previously published data would indicate that IL-33
promotes macrophage alternative activation by inducing secretion
of IL-4 or IL-13 by accessory cells such as eosinophils and ILC2s
(Supporting Information Fig. 3). Alternative activation may be
further promoted by the ability of IL-33 to up-regulate the IL-4Rα
on macrophages.
The interplay between IL-33R and IL-4Rα signaling may be
particularly important during helminth infection. We observed
a lack of IL-4Rα-dependent alternative activation during filarial
nematode infection of IL-33R-deficient mice. IL-33R deficiency
in this model was previously shown to impair splenic clearance
of microfilariae from peripheral blood [28], a lifecycle stage
that is particularly susceptible to the actions of IL-4Rα-activated
macrophages [29]. As microfilarial clearance is dependent on the
spleen [28], it would be of interest to determine which splenic cell
type was responsive to IL-33. In a recent study assessing the role of
IL-33 during experimental malaria, exogenous IL-33 had a major
impact on the spleen [15]. Consistent with our findings in the
peritoneal cavity, IL-33 delivery induced alternatively activated
macrophages accompanied by expansion of both eosinophils and
ILC2s. The authors conclude that ILCs are the major IL-33 target
in the spleen as depletion of the eosinophils did not alter the con-
sequences of exogenous IL-33 delivery on disease outcome [15].
Far more surprising than the dependent relationship between
IL-4 and IL-33 was our discovery that each cytokine was able
to independently drive macrophage proliferation. In the experi-
mental malaria study described above an increase in macrophage
numbers in the spleen was noted following delivery of exoge-
nous IL-33 but it was not determined whether this was occurring
via proliferation or recruitment [15]. Similarly, during Listeria
monocytogenes infection, hepatocyte derived IL-33 was found to
increase macrophage proliferation in the liver [16], and assumed
to be due to an amplification loop acting via basophil production
of IL-4. It will be important to address in the context of Listeria
whether IL-33 can act independently of IL-4 to induce macrophage
proliferation. Delivery of Alternaria intra-nasally resulted in the
proliferation of pleural cavity macrophages in both IL-4Rα defi-
cient and IL-33R deficient animals, suggesting that either receptor
may be sufficient.
Our data do not allow us to state conclusively that IL-33
released following Alternaria delivery acts directly on the
macrophage to cause division. We have previously shown that
IL-4-driven macrophage proliferation is independent of the
requirement for CSF1R signaling and that pleural cavity
macrophage proliferation during L. sigmodontis involves both
CSF1 and IL-4Rα [6]. CSF1 may thus be the mitogen induced by
Alternaria delivery that results in the proliferation of pleural cav-
ity macrophages, independently of both IL-4Rα and IL-33R. Oth-
ers have described the ability of IL-33 to induce the proliferation
C© 2016 The Authors. European Journal of Immunology published by
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of B1-cells, a cell population that makes up a large proportion of
the immune cells within the serous cavities [30]. More recently,
it has been shown that sorted B1b cells placed into culture with
IL-33 will secrete CSF2 (GM-CSF) [31] which leads to the alter-
native possibility that IL-33 may induce CSF2 from B-cells within
the serous cavities, which then contribute to the proliferation of
resident serous macrophages. Future experiments will be required
to determine whether the action of IL-33 on macrophages requires
cell-intrinsic expression of the IL-33R andwhether there is require-
ment for B-cell derived CSF2 in the IL-33 driven macrophage pro-
liferation system. Unraveling the contribution of CSF2 or CSF1 to
IL-33 driven macrophage proliferation will be critical, as pathol-
ogy associated with chronic Th2 settings are characterized by ele-
vated IL-4 and IL-33 [32]. If both cytokines are independently
driving macrophage proliferation, this could prove to have seri-
ous consequences. However, IL-4 exposure in vivo results in the
down-regulation of Csf1r gene expression on macrophages [6]
potentially mitigating the combined effect if CSF1 is involved.
Finally, the data we present here demonstrates a close interac-
tion between an inflammatory response occurring in the lung,
and the activation of immune cells within the pleural cavity.
Our findings, both with IL-33 delivery and Alternaria instilla-
tion, demonstrate that airway inflammation triggers a concurrent
inflammation within the pleural space, which in turn modulates
macrophage phenotype. A close interaction between lung infec-
tion/inflammation and pleural cavity activation is likely to prove
relevant to a wide range of conditions. For example 4–10% of all
pulmonary tuberculosis cases results in pleural effusion [33, 34].
The activation of immune cells within the pleural space during
this infection is thought to be dependent upon the presence of
mycobacterium antigens within the pleural cavity [34, 35], high-
lighting the ability of lung derived antigens to traffic to the pleural
space. The pleural cavity is also a known site at which proxi-
mal lung cancers metastasise, and can result in malignant pleural
effusion [36]. Our new data show that IL-33 delivery in vivo can
induce the proliferation of macrophages independently of IL-4Rα
signaling and serve to highlight an important but often overlooked
interaction between the lungs and the serous cavity in which they
reside.
Materials and methods
Animals, infections, and airway allergy models
Experiments were performed using BALB/c, BALB/c Il4ra−/−,
BALB/c dblGATA [37], and BALB/c Il1rl1−/- animals that were
maintained under specific pathogen–free conditions at the Univer-
sity of Edinburgh or University ofManchester Animal Facilities and
used at 6–12 weeks of age. Mice were sensitized intra-nasally with
50 μg Alternaria alternata extract (Greer) in 50 μL dPBS (Sigma),
50 μL dPBS alone at time 0, or 200 ng rIL-33 (Peprotech) in
50 μL dPBS at time 0 and again at 24 h, all intra-nasally sensitized
animals were culled at 48 h following initial instillation. Mice were
infected via sub-cutaneous injection into the scruff with 30 Lito-
mosoides sigmodontis L3s in 200 μL of RPMI 1640 (Invitrogen)
containing 5% horse serum, or vehicle alone and all animals were
culled 11 days later. Mice were injected intra-peritoneally with
500 ng rIL-33 (Peprotech), or 5μg rIL-4 (Peprotech) complexed to
25μg anti-IL-4 antibody (clone 11B11; BioXcell) in dPBS (Sigma),
or dPBS (Sigma) alone, peritoneal cells were harvested after 48 h.
All experiments were approved under a Project License granted
by the Home Office (UK) and conducted in accordance with local
guidelines.
Cell isolation and culture
Pleural and peritoneal exudate cells were isolated via flushing
the cavity with RPMI 1640 (Invitrogen) containing 50 U/mL peni-
cillin, 50μg/mL streptomycin (Invitrogen) and 2mM L-Glutamine
(Invitrogen), 1 mL of the first 2 mL of wash was frozen for later
ELISA analysis. Erythrocytes were removed by incubating with
red blood cell lysis buffer (Sigma). Cellular content of the cavi-
ties was assessed by cell counting using a Cellometer R© Auto T4
Cell Counter (Nexcelom Bioscience) in combination with multi-
color flow cytometry. For detection of intracellular cytokines in
Fig. 1, cells were stimulated for 4 h at 37°C with PMA (phorbol
myristate acetate; 0.5 μg/mL; Sigma) and ionomycin (1 μg/mL;
Sigma) including brefeldin A (10 μg/mL; Sigma) for the last 3 h
of incubation. Cells were then surface stained, fixed and perme-
abilized as below. In vitro stimulation: Peritoneal exudate cells
were isolated from na¨ıve BALB/c or na¨ıve Il1rl1−/− animals as
described above, spun down and seeded as biological replicates in
96 well plates at 1 × 106/mL in 200 μL of RPMI (Invitrogen) con-
taining 10% Fetal Bovine Serum, 50 U/mL penicillin, 50 μg/mL
streptomycin (Invitrogen), and 2mM L-Glutamine (Invitrogen). 2,
20, or 200 ng/mL rIL-33 (Peprotech) was included in each well,
cells were incubated at 37°C, 5% CO2 for 40 h. Supernatants were
removed, and cells were stained within the same plate for analysis
by flow cytometry.
Flow cytometry
Samples were washed twice in PBS prior to staining with
LIVE/DEAD (Life Technologies) for 10 min at room temperature.
Samples were then blocked with 5 μg/mL anti CD16/32 (clone
2.4G2; produced in house) and heat-inactivated mouse serum
(1:10) in FACs Buffer (dPBS containing 0.5% BSA (Sigma), 2mM
EDTA (Sigma)) cell surface markers for several different cell
populations were detected by addition of various flourochrome-
conjugated antibodies (See Supporting Information Table I for
list of antibodies used) for 20–30 min on ice. Samples were
washed in FACs buffer prior to intracellular staining which was
performed following fixation in either 2% formaldehyde for
10 min at room temperature or 1× Fixation/Permeabilization
buffer (eBioscience) overnight followed by permeabilization
using 1× permeabilization buffer (eBioscience). Antibod-
ies to detect intracellular proteins (including Ki67 clone
C© 2016 The Authors. European Journal of Immunology published by
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B56 from BD) were incubated with samples on ice in per-
meabilization buffer (eBioscience) for 30 min. Samples
were acquired using a BD LSR II. Macrophages were gated
as CD19−Ly6G−SigF−TCRβ−F4/80hiMHC-IIlo, Eosinophils
were gated as SigF+SSChiMHC-II−, ILC were gated as
CD3−CD11c−B220−Ly6G−Ly6C−F4/80−CD11c−NK1.1−Ter119−
CD5−CD11b−CD49b−CD45.2+CD90.2+.
ImageStream
Samples were blocked with 5 μg/mL anti CD16/32 (clone 2.4G2;
produced in house) in ImageStream buffer (dPBS containing 1%
FCS (Sigma), 2mM EDTA (Sigma)). Cells were stained for F4/80
PE (Clone: BM8 (BioLegend)) for 25 min at 4°C. Samples were
washed in ImageStream buffer and fixed in 1% paraformalde-
hyde for 10 min at room temperature followed by permeabiliza-
tion with Fixation/ Permeabilisation buffer (eBioscience) for 30
min at 4ºC and washed with 1× permeabilization buffer (eBio-
science). Samples were stained with TOPRO3 (1:2000) for 10 min
at room temperature and washed once with FACS buffer ready
to acquire on the ImageStream. Data acquisition was performed
on ImageStreamX (Amnis/EMD Millipore, Seattle, WA) equipped
with 405, 488, 561, and 642 nm lasers. Single cells were dis-
criminated from cell aggregates based on area and aspect ratio,
in focus macrophages were selected based on high gradient RMS
of the bright field image and F4/80 expression. The F4/80+ gate
was drawn based on an FMO control and a minimum of 5000
F4/80+ cells were collected run at a low flow rate setting. Images
of cells were acquired with a ×40 objective including bright field
images (Channels 1 & 9; 430–480nm) F4/80 PE (Channel 3; 560–
595nm), TOPRO3 (Channel 11; 660–740nm). All data analysis
was performed using the IDEAS R© software version 6.
Antigen preparation
Alternaria extract (Greer) (Alt) was dissolved in PBS and filter
sterilized.
ELISAs
Sandwich ELISAs were used to detect RELMα (Peprotech) and
Ym1 (R&D Systems) within the peritoneal lavage and pleural
lavage fluid. Plates were developed using 2-part TMB reagent (KPL
& Biolegend).
Statistical analysis was performed using Prism 6 for Mac OS
X (v6.0d, GraphPad Software). Statistical tests used are described
in each figure legend.
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